Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STP 369

Next Previous
Drug Profile

STP 369

Alternative Names: STP-369

Latest Information Update: 25 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirnaomics
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Bcl-X protein inhibitors; MCL1 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Head and neck cancer

Most Recent Events

  • 05 Oct 2021 Sirnaomics plans to file IND application to initiate clinical trial of STP 369 in Head and neck cancer and Bladder cancer, in 2023
  • 05 Oct 2021 Sirnaomics has patent pending for STP 369 in USA, China
  • 05 Oct 2021 Preclinical trials in Bladder cancer in USA (Intratumoural)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top